New Massachusetts legislation bans the sale of menthol products; a group of hospitals is suing HHS; the FDA has approved a new treatment for partial-onset seizures.
A bill passed by Massachusetts lawmakers would ban sales of flavored tobacco and vaping products, including menthol cigarettes, according to the Associated Press, as well as impose a 75% excise tax on vaping products and require insurers to cover counseling for tobacco cessation. It was in September that Governor Charlie Baker first introduced a temporary 4-month ban, although he has not yet indicated whether he will sign the new bill. If it goes into law on June 1, 2020, it would be the first law of its kind in the nation.
Thirteen hospitals and Capital Health System have filed a lawsuit in the US District Court for the District of Columbia against HHS and HHS Secretary Alex Azar, according to Bloomberg Law. The hospitals claim they were not correctly reimbursed for services provided to low-income patients after a 2014 change in the calculation of such payments. They seek a declaration that the HHS decision is invalid and an order of new recalculation and repayment, along with attorneys’ fees and costs.
Based on findings from 2 studies, yesterday the FDA approved cenobamate (Xcopri), a new antiepileptic drug from SK Life Science that treats partial-onset seizures in adults. The drug has a maximum recommended dose of 400 mg when necessary, but in most cases, the dose will be 200 mg daily. Possible adverse effects include changes in mood or behavior, sleepiness, and headaches.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Use of AI Lets Health System Find Lung Cancer at Early Stages
March 8th 2025Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen